


## **Evidence-based recommendations for nextgeneration sequencing germline variant confirmation**

## May 18 2023



Technical criteria. Traditionally, a single set of criteria (or filters) has been used to separate high-quality next-generation sequencing variant calls from those that may be analytic false positives. In the recommended framework, laboratories should use two levels of criteria: filters (bottom arrow) intended to remove variant calls that are likely false positives and that should not be reported; and much stricter criteria, intended to separate the highest confidence calls, likely true positives, from those of lower quality that may or may not be true. Using two (or more) levels of criteria with orthogonal confirmation can improve both specificity and, indirectly, sensitivity (see Technical Background). Criteria in both cases should be validated and may include quality metrics, genomic context, and other factors (see Recommendation 5). Credit: *The Journal of Molecular Diagnostics* (2023). DOI: 10.1016/j.jmoldx.2023.03.012



The Association for Molecular Pathology (AMP) has published a report that was designed to establish recommendations for standardizing orthogonal confirmation practices for germline variants detected by nextgeneration sequencing (NGS).

The manuscript, "Recommendations for Next-Generation Sequencing Germline Variant Confirmation: A Joint Report of the Association for Molecular Pathology and National Society of Genetic Counselors," was released online ahead of publication in *The Journal of Molecular Diagnostics*.

"While NGS has quickly transformed the field of clinical molecular genetic testing, orthogonal confirmation practices for germline variants may vary between laboratories," said Kristy R. Crooks, Ph.D., Associate Professor and Laboratory Director at the University of Colorado Anschutz Medical Campus, and Chair of the AMP NGS Germline Variant Confirmation Working Group.

"This new report provides recommendations for orthogonal confirmation practices that, in concert with existing guidelines, are designed to help promote standardization, transparency, and quality improvement among laboratories."

The AMP Clinical Practice Committee convened the NGS Germline Variant Confirmation Working Group to assess current evidence and standardize orthogonal confirmation practices to help limit the reporting of false positives. The new report offers the following eight recommendations that are based on a comprehensive review of published literature, <u>empirical data</u>, current laboratory practice surveys, feedback from open public comment, and professional experiences.

1. Clinical laboratories offering germline testing using NGS should establish a written policy regarding orthogonal confirmation of



NGS results.

- 2. Laboratories' orthogonal confirmation policy should be overseen and approved by a qualified and appropriately certified medical professional with training and experience in NGS.
- 3. Laboratories' confirmatory methods, platforms, and associated bioinformatics should be validated and maintained under appropriate regulatory oversight as for other aspects of the test.
- Laboratories' confirmatory methods should be orthogonal. Discrepant results between NGS and a confirmatory assay should be investigated and resolved, rather than accepting any one methodology to be always correct.
- 5. Laboratories should perform confirmatory testing for reported germline variants with significant clinical implications, except for <u>variant</u> calls meeting technical criteria rigorously demonstrated to ensure high positive predictive value from NGS alone.
- 6. Laboratories should clearly articulate their specific policies, criteria, and methods regarding orthogonal confirmation in written materials readily available upon request.
- 7. Laboratories' clinical test reports should summarize orthogonal confirmation policy in every report, and when exceptions to the policy are made, these should be clearly indicated.
- 8. Special considerations apply to certain NGS-based test types and findings.

"This new report was meant to summarize the current collective state of knowledge and guide clinical <u>laboratory</u> professionals regarding orthogonal confirmation of germline variants," said Susan Hsiao, MD, Ph.D., Associate Professor of Pathology and Cell Biology at Columbia University Vagelos College of Physicians and Surgeons, and 2023 AMP Clinical Practice Committee Chair. "AMP will continue to reassess and modify our guidelines as the methodology and bioinformatics underlying NGS-based variant detection develop as part of our ongoing



commitment to improving <u>clinical practice</u> and patient care."

**More information:** Kristy R. Crooks et al, Recommendations for Next-Generation Sequencing Germline Variant Confirmation, *The Journal of Molecular Diagnostics* (2023). DOI: 10.1016/j.jmoldx.2023.03.012

Provided by Association for Molecular Pathology

Citation: Evidence-based recommendations for next-generation sequencing germline variant confirmation (2023, May 18) retrieved 4 July 2024 from <u>https://medicalxpress.com/news/2023-05-evidence-based-next-generation-sequencing-germline-variant.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.